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Arrhythmogenic right ventricular dysplasia/cardiomyopathy
(ARVD/C) is considered a hereditary cardiac disease,
characterised by ventricular arrhythmias with left bundle
branch block morphology, fibro-fatty replacement of
cardiomyocytes and predominantly affecting the right ven-
tricle [1, 2]. Recently, arrhythmogenic cardiomyopathy
(AC) was suggested as the preferred terminology [3]. The
most important considerations for this are that patients and
families with ventricular arrhythmia and similar ARVD/C
histopathological changes in the left ventricle have been
recognised and described as left-dominant arrhythmogenic
cardiomyopathy [4]. Mutations in desmosomal genes are
associated with both ARVD/C and left-dominant
arrhythmogenic cardiomyopathy and at the molecular level
both ventricles and the interventricular septum are similarly
affected [5, 6].
Classically AC is considered a disease of the desmo-
somes. Desmosomes are protein complexes located in the
intercalated disk, important for mechanical integrity. For
example, in approximately 60 % of Dutch AC patients a
pathogenic desmosomal mutation is found, predominantly
in the PKP2 gene [7]. Non-desmosomal genes have also
been identified in families with phenotypical AC, for exam-
ple TMEM43 [8]. Another mutation in a non-desmosomal
gene is the p.Arg14del mutation in the phospholamban
(PLN) gene. Phospholamban is involved in calcium homeo-
stasis in the sacroplasmatic reticulum of the cardiac muscle
cell [9]. Mutation carriers are phenotypically characterised
by low-voltage electrocardiograms, ventricular arrhythmias,
and contractile dysfunction involving both ventricles.
Van der Zwaag et al. found that the PLN mutation was
especially prevalent in the Netherlands, both in dilated car-
diomyopathy (13 %) as well as in AC (12 %) [10]. This was
a surprising finding because in other cohorts the prevalence
of the PLN p.Arg14del mutation was found to be very low,
between 0.08 % and 0.38 % [11]. In this issue of the Journal,
Van der Zwaag et al. describe the origin of the PLN
p.Arg14del founder mutation in the Netherlands [11]. This
paper fits nicely in a series of articles started in 2009 on
founder mutations in the Netherlands in different cardiomy-
opathies [12]. Founder mutations are mutations that
emerged in a population many generations ago and have
subsequently spread among following generations.
In the study by Van der Zwaag et al. [11]. a large number
of PLN p.Arg14del founder mutation carriers (probands and
family members) were identified, in total 459 individuals.
The authors analysed the origin of the PLN founder muta-
tion first by haplotype analysis revealing that the mutation is
estimated to be between 575 and 825 years old. Subsequent-
ly, in order to approximate the geographical origin of the
PLN mutation the places of birth of the grandparents of the
probands were plotted on a postal code map of the Nether-
lands, revealing that the majority of the grandparents came
from the eastern part of the Dutch province of Friesland.
The grandparents included in this study were born roughly
between 1900 and 1925, i.e. approximately 75 to 100 years
ago. At least six centuries of history are not accounted for,
while in this time a lot happened. A quick search on the
internet reminds us of the many wars the Dutch (including
the ‘Friezen’) had with different enemies (e.g. Swedish,
Spanish and Germans). The haplotype in the German family
was the same as the haplotype found in the Dutch families,
J. F. van der Heijden (*) : R. J. Hassink
Department of Cardiology, University Medical Center Utrecht,
Huispostnummer: E03.511, Heidelberglaan 100, P.O. Box 85500,
3508 GA Utrecht, the Netherlands
e-mail: j.f.vanderheijden-2@umcutrecht.nl
Neth Heart J (2013) 21:284–285
DOI 10.1007/s12471-013-0413-z
rising the possibility that the PLN founder mutation was
introduced in Friesland by a German soldier, who possibly
found a new love in Friesland. Also, due to migration, the
residential area of the ‘Friezen’ around 1300 ran from the
province of Noord-Holland up to Denmark. Therefore, it is
still not sure that the origin of the mutation is in Friesland. A
more detailed study of the migration in Friesland is needed
to elucidate the exact place of origin of the PLN mutation;
however, this is probably impossible, without the necessary
registries.
The authors subsequently studied the prevalence of the PLN
p.Arg14del mutation in the PREVENT cohort, a large
population-based cohort from the city of Groningen, in the
north of the Netherlands (N=8267). In this cohort six hetero-
zygous PLN mutation carriers were found (0.07 %). As mi-
gration in the Netherlands has been very limited, as stated by
the authors, the PREVENT cohort is possibly not the best
cohort to test the true prevalence of the mutation in the Neth-
erlands. Possibly the prevalence of the PLN founder mutation
can be more accurately determined in other Dutch cohorts, not
specifically including patients from the north of the country
(e.g. ERGO, Rotterdam or SMART study, Utrecht).
Of particular interest is the great difference in clinical
expression in mutation carriers in the different families as
shown by the family presented by the authors. This phe-
nomenon is present in many different cardiomyopathies
(e.g. hypertrophic cardiomyopathy) and primary electric
cardiac diseases (e.g. long-QT syndrome). Different possible
answers are the presence of polymorphisms influencing the
calcium handling in the cardiac myocyte or related genes.
Recently, the down-regulation of the cardiac sodium chan-
nel was found to be important in arrhythmogenesis in
plakophylin-2 haploinsufficient mice13 and is possibly a
predictor for SCD in patients with AC, making SCN5A
another possible modulating gene, for example. Further-
more, differences between family members in the suscepti-
bility for fibrosis in the heart could be of importance.
Finally, there might be regions in the Netherlands with
specific ‘environmental influences’ that make people more
susceptible for developing a more severe phenotype.
As mentioned before, in the PREVENT cohort six car-
riers of the PLN mutation were found and one of them
developed heart failure within 10 years of follow-up
(17 %). The question is whether it is mandatory to identify
all carriers of the PLN mutation to be able to screen these
individuals for risk factors for sudden cardiac death and/or
heart failure. As the authors already state the PHORECAST
study is an important tool to investigate the questions about
risk stratification for sudden cardiac death and development
of heart failure, consequently these findings should give rise
to treatment strategies to prevent these severe complications.
In conclusion, the PLN p.Arg14del founder mutation
appears to originate from the north of Friesland. In the near
future the goal should be to identify all carriers of the PLN
p.Arg14del mutation to be able to prevent SCD and possibly
treat asymptomatic carriers to prevent progression to
disease.
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